The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia

BMC Infect Dis. 2013 Jul 3:13:304. doi: 10.1186/1471-2334-13-304.

Abstract

Background: This analysis assessed the epidemiological and economic impact of quadrivalent human papillomavirus (HPV4: 6/11/16/18) vaccination in Estonia.

Methods: A dynamic transmission model was used to assess the epidemiological and economic impact of the routine vaccination of 12-year-old girls with a HPV4 vaccine in preventing cervical cancer, cervical intraepithelial neoplasia (CIN) grades 1, 2 and 3 and genital warts.

Results: The model projected that at year 100, HPV4 vaccination would lead to a reduction of HPV 16/18 related cervical cancer incidence and deaths by over 97% and the incidence of HPV 6/11 related genital warts among Estonian women and men by over 94% and 81%, respectively. The incremental cost-effectiveness ratio of the HPV4 vaccination strategy was € 4,889 per QALY gained over a time horizon of 100 years.

Conclusions: Routine vaccination of 12-year-old girls with HPV4 vaccine appears to be cost-effective in Estonia, in addition to providing both short term and long term health gains.

MeSH terms

  • Child
  • Condylomata Acuminata / epidemiology
  • Cost-Benefit Analysis
  • Estonia / epidemiology
  • Female
  • Humans
  • Male
  • Models, Biological
  • Models, Statistical
  • Papillomavirus Infections / economics*
  • Papillomavirus Infections / epidemiology*
  • Papillomavirus Infections / prevention & control
  • Papillomavirus Vaccines / administration & dosage*
  • Papillomavirus Vaccines / economics*
  • Papillomavirus Vaccines / immunology
  • Reproducibility of Results
  • Uterine Cervical Dysplasia / epidemiology
  • Uterine Cervical Neoplasms / epidemiology
  • Vaccination / statistics & numerical data

Substances

  • Papillomavirus Vaccines